This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Liver Phosphorylase Kinase Deficiency / GSD Type IX / X-linked Hepatic Glycogenosis간인산화효소결핍

Contents and key points
ItemDetails
A. Classification codesICD-10: E74.0 (glycogen storage disease) | Special Copayment Reduction: V117 (ultra-rare disease)
B. SynonymsGlycogen storage disease type IX, GSD IXa (PHKA2 deficiency, X-linked), GSD IXb (PHKB deficiency, autosomal recessive), X-linked liver glycogenosis (XLG I·II), Phosphorylase kinase deficiency, Liver PhK deficiency, PHKA2-related GSD, PHKB-related GSD
C. Adult onsetLikelihood of first onset in adulthood low — mostly diagnosed in childhood from hepatomegaly. However, male carriers of mild GSD IXa or patients with mild PHKB variants may first be diagnosed in adulthood. In some cases, the underlying diagnosis is made when patients present in adulthood with complications of liver cirrhosis or hepatocellular carcinoma.
1. HistoryPhosphorylase kinase deficiency first described in the 1960s. In the 1990s, identification of the PHKA2 (Xp22.13) gene established X-linked liver glycogenosis at the molecular level.
2. CausesPHKA2 (Xp22.13, X-linked) or PHKB (16q12.1, autosomal recessive) variants → liver phosphorylase kinase (PhK) deficiency → inability to activate glycogen phosphorylase → excessive hepatic glycogen accumulation.
3. GeneticsGSD IXa: PHKA2 X-linked, affects males. GSD IXb: PHKB autosomal recessive, males and females equally. GSD IXc: PHKG2 autosomal recessive, severe hepatic form.
4. General epidemiologyOne of the most common forms of glycogen storage disease. Prevalence about 1/100,000. About 25% of all GSD. GSD IXa accounts for 75%.
5. PathophysiologyPhK deficiency → inability to activate glycogen phosphorylase b→a → blocked hepatic glycogen breakdown during fasting → hepatic glycogen accumulation, fasting hypoglycemia, ketoacidosis.
6. SymptomsHepatomegaly, growth retardation, fasting hypoglycemia, ketoacidosis, hypertriglyceridemia. GSD IXa: hepatic symptoms predominate. GSD IXb: liver + muscle involvement possible. GSD IXc (PHKG2): high risk of liver cirrhosis.
7. SignsHepatomegaly (on palpation), elevated ALT/AST/GGT, low fasting glucose, positive ketones, elevated triglycerides. Normal blood lactate (distinguishing point from GSD I).
8. ScreeningFasting metabolic panel for children with hepatomegaly. PhK activity can be measured in erythrocytes and leukocytes (not the liver-specific isoform — genetic testing needed for confirmation).
9. DiagnosisMolecular genetic testing of the PHKA2, PHKB, and PHKG2 genes (confirmation). Hepatic PhK enzyme activity (if needed). Molecular differentiation from Hers disease (GSD VI, PYGL) essential.
10. TreatmentUncooked cornstarch, high-protein, low-carbohydrate diet. Continuous overnight enteral feeding (if needed). Regular monitoring for hepatic complications.
11. PrognosisGSD IXa: tendency to improve spontaneously after puberty, generally favorable. GSD IXb: variable, including muscle symptoms. GSD IXc (PHKG2): high risk of liver cirrhosis and hepatocellular carcinoma, requiring active management.
12. PreventionGenetic counseling (including female carriers of X-linked GSD IXa), dietary management, regular imaging follow-up.
13. ReferencesSovik O et al. (1976) first description of PhK deficiency and 9 other papers.

1. History

The history of liver phosphorylase kinase deficiency (GSD IX) begins in the late 1960s, when a new subtype of glycogen storage disease was described in pediatric patients with disorders of hepatic glycogen metabolism. Initially, because the clinical symptoms were similar to Hers disease (GSD VI), the two diseases were reported together, and in some patients it was called "pseudo-Hers disease" or "X-linked liver glycogenosis (XLG)."

In the 1970s~1980s, as enzyme assay techniques advanced, it was established that what is deficient is not hepatic glycogen phosphorylase (liver glycogen phosphorylase) itself but the upstream enzyme that activates it, phosphorylase kinase (PhK). PhK is a hexadecameric (α₂β₂γ₂δ₂) complex consisting of four subunits, α, β, γ, and δ, each encoded by a different gene. The liver-specific isoform of the α subunit is encoded by the PHKA2 gene, the β subunit by the PHKB gene, and the liver/testis-specific isoform of the γ subunit by the PHKG2 gene.

With advances in molecular biology techniques in the 1990s, the PHKA2 gene was found to be located on the short arm of the X chromosome (Xp22.13), establishing that GSD IXa, the most common subtype of GSD IX, arises through X-linked inheritance. Subsequently, the genes PHKB (16q12.1), PHKG2 (16p11.2), and PHKA1 (Xq13) were also identified, revealing that GSD IX is a heterogeneous group composed of various genetic subtypes. Since the 2000s, with the introduction of NGS technology, many patients previously misdiagnosed with Hers disease (GSD VI) have been rediagnosed with GSD IXa or IXb, and molecular differentiation of the two diseases has become standardized in clinical practice. In Korea, too, GSD IX has come to be recognized in pediatrics as an important differential diagnosis among the causes of hepatomegaly, and as of 2025, analyses of domestic patient cohorts are under way at some institutions.


2. Causes

Liver phosphorylase kinase deficiency (GSD IX) is an inherited glycogen storage disease caused by pathogenic variants in genes encoding the liver-specific subunits of phosphorylase kinase (PhK). PhK catalyzes the phosphorylation that converts glycogen phosphorylase from its inactive form (phosphorylase b) to its active form (phosphorylase a). When PhK itself is deficient, glycogen phosphorylase cannot be activated, and consequently glycogen breakdown is blocked, leading to excessive glycogen accumulation in the liver.

GSD IX is classified into subtypes according to the gene involved, as follows. GSD IXa (PHKA2, Xp22.13): the most common subtype, X-linked inheritance. Deficiency of the liver/erythrocyte-specific isoform of the α subunit (αL). Mainly affects males. Female carriers are usually asymptomatic but may have mild symptoms. GSD IXb (PHKB, 16q12.1): autosomal recessive inheritance. β subunit deficiency. Both liver and muscle affected (shared muscle-type PhK β subunit). GSD IXc (PHKG2, 16p11.2): autosomal recessive inheritance. Deficiency of the liver-specific isoform of the γ subunit (γT). The most severe hepatic phenotype, with high risk of liver cirrhosis and hepatocellular carcinoma. GSD IXd (PHKA1, Xq13): X-linked. Deficiency of the muscle-specific isoform of the α subunit. Mainly a muscle phenotype.

GSD IX is clinically very similar to Hers disease (GSD VI, PYGL deficiency). Both diseases show hepatomegaly, fasting hypoglycemia, ketoacidosis, and growth retardation. The fundamental difference is that in GSD VI the phosphorylase itself is deficient, whereas in GSD IX the activating enzyme of phosphorylase (PhK) is deficient. Because it is practically impossible to distinguish the two diseases without molecular genetic testing, gene panel testing including GSD IX and GSD VI is recommended as the diagnostic standard.


3. Genetics

The mode of inheritance and genes involved in GSD IX differ by subtype. GSD IXa (PHKA2): the PHKA2 gene is located on the short arm of the X chromosome (Xp22.13). With X-linked inheritance, in males (hemizygous) a single variant allele is enough for the disease to manifest. Female heterozygotes (carriers) are usually asymptomatic, but some may show mild symptoms depending on unequal X-chromosome inactivation (lyonization). Because GSD IXa is X-linked, for a female to be affected both X chromosomes must carry PHKA2 variants, which is very rare. When the mother is a carrier, 50% of sons are affected.

GSD IXb (PHKB): the PHKB gene is located on chromosome 16 (16q12.1) and shows autosomal recessive inheritance. Because PHKB encodes the PhK β subunit common to all tissues, variants affect both liver and muscle, and mild muscle weakness and myopathy may accompany hepatomegaly. The clinical phenotype of GSD IXb is more variable than that of GSD IXa, and some patients show a more severe course.

GSD IXc (PHKG2): the PHKG2 gene is located on chromosome 16 (16p11.2) and shows autosomal recessive inheritance. PHKG2 encodes the γ subunit in the liver and testis. GSD IXc shows the most severe hepatic phenotype, and the risk of liver cirrhosis and hepatocellular carcinoma (HCC) is significantly elevated, requiring active long-term follow-up. In some patients with PHKG2 variants, hepatocellular carcinoma has developed in childhood and adolescence.

To date, tens to about 100 pathogenic variants have been reported in each gene, including missense, nonsense, frameshift, and splicing variants. Genotype–phenotype correlations are partly established but incomplete. For PHKA2 variants, missense variants tend to preserve residual enzyme activity and produce milder phenotypes than nonsense and frameshift variants that block protein synthesis. PHKG2 nonsense variants are associated with a severe hepatic phenotype and a high HCC risk.


4. General epidemiology

Liver phosphorylase kinase deficiency (GSD IX) is one of the most common of all forms of glycogen storage disease and is known to account for about 25% of all GSD. The estimated worldwide prevalence is about 1/100,000 births, and the actual prevalence is presumed to be higher when undiagnosed mild cases are included. Considering that in the past a substantial number of GSD IX cases (especially GSD IXa) were misdiagnosed as Hers disease (GSD VI), historical prevalence data may have been underestimated.

By subtype, GSD IXa (PHKA2, X-linked) is the most common form, accounting for about 75% of all GSD IX. Because of X-linked inheritance, it mainly affects males, so patients with this subtype are almost all male. GSD IXb (PHKB) accounts for about 15~20% and GSD IXc (PHKG2) for about 5~10%. Some ethnic- or region-specific founder effects have been reported, but GSD IX occurs in all ethnic groups worldwide.

In Korea, GSD IX is diagnosed in pediatric endocrinology and genetic metabolism clinics as a major cause of hepatomegaly, and GSD IXa is reported to account for most domestic patients. The exact number of registered patients in Korea is not known, but it is included on the Korea Disease Control and Prevention Agency (KDCA) list of ultra-rare diseases. Age at diagnosis is mostly between 1 and 5 years, and patients are often first referred for hepatomegaly, abdominal distension, and growth retardation. Because GSD IXa is X-linked, active testing of brothers is recommended when the mother is a carrier.


5. Pathophysiology

In normal hepatic glycogenolysis, glucagon or epinephrine stimulation activates hepatocyte adenylyl cyclase, increasing cAMP. The increased cAMP activates protein kinase A (PKA), and PKA phosphorylates the α and β subunits of phosphorylase kinase (PhK), activating PhK. Activated PhK in turn phosphorylates Ser14 of glycogen phosphorylase b (inactive form), converting it to the active form, glycogen phosphorylase a, and thereby initiating glycogen breakdown.

When PhK is deficient in GSD IX, an intermediate step of this signaling cascade is blocked. cAMP elevation and PKA activation occur normally, but PhK cannot activate glycogen phosphorylase b. As a result, glycogen phosphorylase remains in its inactive form, hepatic glycogen breakdown does not occur during fasting, and glycogen accumulates abnormally in the liver. This is the mechanism of hepatomegaly and liver dysfunction.

The differences between Hers disease (GSD VI) and GSD IX are as follows. In GSD VI, glycogen phosphorylase itself (the PYGL product) is deficient, so even if PhK is normal, no reaction occurs because the substrate enzyme is absent. In GSD IX, glycogen phosphorylase is normal but the PhK that activates it is absent, so the functional result is similar. Both diseases show hypoglycemia and ketoacidosis during fasting, but hypoglycemia in GSD IX is generally known to be milder than in GSD VI. PhK also functions as a glycogen synthase kinase and serves to inhibit glycogen synthesis, so PhK deficiency aggravates excessive glycogen accumulation through a dual mechanism in which blocked glycogen breakdown is accompanied by stimulation of glycogen synthesis.

Muscle PhK is also partly affected in GSD IXb (PHKB deficiency) because the β subunit is used in common by liver and muscle PhK. As a result, some GSD IXb patients have accompanying muscle weakness and exercise intolerance. GSD IXc (PHKG2 deficiency) shows a more severe hepatic phenotype because the γ subunit, the PHKG2 product, is the catalytic subunit of PhK (kinase catalytic core), so its deficiency causes complete loss of PhK catalytic function, resulting in more extensive impairment of glycogen breakdown.


6. Symptoms

The clinical symptoms of liver phosphorylase kinase deficiency (GSD IX) are generally similar to those of Hers disease (GSD VI), but additional symptoms may accompany it depending on subtype.

Common symptoms (all GSD IX subtypes): hepatomegaly is the most characteristic finding, present in almost all patients. Liver enlargement with abdominal distension is observed from infancy and early childhood, caused by hepatic glycogen accumulation. Growth retardation appears due to hypoglycemia and chronic energy deficiency, with height and weight at low percentiles relative to peers. Fasting hypoglycemia is mainly mild to moderate and worsens with prolonged fasting (overnight, fasting due to fever). Ketoacidosis appears as elevated ketone bodies due to increased fatty acid oxidation during fasting and can cause nausea, vomiting, and abdominal pain. Hypertriglyceridemia and elevated liver function values (ALT, AST, GGT) accompany it.

Symptoms specific to GSD IXa (PHKA2): hepatic symptoms predominate, with no muscle involvement. It manifests only in boys, symptoms are often relatively mild, and there is a tendency toward spontaneous improvement after puberty.

Symptoms specific to GSD IXb (PHKB): in addition to hepatic symptoms, mild muscle weakness, myalgia, and exercise intolerance may accompany it. This is because the β subunit is used in common by liver and muscle PhK. The degree of muscle involvement varies greatly between individuals.

Symptoms specific to GSD IXc (PHKG2): the most severe phenotype, with prominent severe hypoglycemia and growth retardation from early childhood. If left untreated, the risk of progression to liver cirrhosis is high, and there are reported cases of hepatocellular carcinoma (HCC) developing in childhood and adolescence. Some patients may have accompanying renal tubular abnormalities (Leconi syndrome-like) and hypotonia.


7. Signs

Physical findings: hepatomegaly is most characteristic; on palpation, the lower edge of the liver extends 2~10 cm below the right costal margin. The liver is soft rather than firm and is often nontender on palpation. Splenomegaly generally does not occur, but in GSD IXc with progressed liver cirrhosis, splenomegaly due to portal hypertension may be observed. Abdominal distension accompanies it, and a "pot belly" appearance may be seen in infants.

Laboratory findings: elevations of serum ALT, AST, and GGT are characteristic (2~10 times the upper limit of normal). Low fasting glucose (mild to moderate), elevated blood ketone bodies, and positive urine ketones are observed on fasting tests. Blood lactate is normal or mildly elevated, a finding that distinguishes it from GSD I, in which lactic acidemia is prominent. Elevated serum triglycerides and mildly elevated uric acid accompany it. The glycemic response to glucagon stimulation is reduced. On measurement of erythrocyte PhK activity, some GSD IXa patients show reduction, but because this is not the liver-specific isoform, it may also be normal, so its use for confirmation is limited.

Imaging findings: abdominal ultrasound shows hepatomegaly and increased hepatic echogenicity (a hyperechoic pattern due to excessive glycogen accumulation), and abdominal MRI shows abnormal hepatic signal intensity. When liver cirrhosis progresses in GSD IXc, irregular liver surface, portal vein dilation, and ascites may be observed on ultrasound, and dynamic contrast-enhanced CT or MRI is needed to differentiate hepatocellular carcinoma.


8. Screening

Because GSD IX is not included in newborn metabolic screening (tandem mass spectrometry), active symptom-based suspicion is the key to early diagnosis. Detailed testing for hepatic glycogenosis including GSD IX should be performed in the following situations. (1) Unexplained hepatomegaly in children aged 1~5 years. (2) Recurrent fasting hypoglycemia and ketoacidosis. (3) Chronically elevated liver enzymes (ALT/AST). (4) Infants and young children with abdominal distension accompanied by growth retardation. (5) Families in which a brother has been diagnosed with GSD IX (especially important for X-linked GSD IXa). (6) Boys in families in which a female carrier has been identified.

Primary biochemical screening: after 6~8 hours of fasting, a metabolic panel including blood glucose, lactate, ketone bodies, uric acid, triglycerides, liver function tests (ALT, AST, GGT, albumin), blood insulin, and cortisol is performed. Ketonemia and hypoglycemia with normal lactate strongly suggest GSD VI or GSD IX. A reduced glycemic response on the glucagon stimulation test suggests impaired hepatic glycogen breakdown.

Phosphorylase activity screening: PhK activity can be measured in erythrocytes or leukocytes. In patients with GSD IXa (PHKA2 deficiency), erythrocyte PhK activity may be reduced (shared liver/erythrocyte isoform of the α subunit), but it may be normal in patients with GSD IXc (PHKG2), so its use for confirmation is limited. Therefore, even if the enzyme activity result is normal, molecular genetic testing proceeds when clinical suspicion is sufficient.


9. Diagnosis

GSD IX is confirmed by molecular genetic testing of the PHKA2, PHKB, and PHKG2 genes. When hepatic glycogenosis is suspected on clinical and biochemical testing, it is most efficient to perform a hepatic glycogenosis gene panel including GSD VI (PYGL), GSD IX (PHKA2/PHKB/PHKG2), GSD III (AGL), and others.

Molecular genetic testing strategy: (1) In male patients, X-linked GSD IXa (PHKA2) is suspected first, and the PHKA2 gene is tested first. (2) In female patients or when cases occur with equal frequency in males and females, autosomal recessive PHKB or PHKG2 is tested. (3) As the standard approach, it is recommended to perform a hepatic glycogenosis gene panel (including PYGL, PHKA2, PHKB, PHKG2, AGL, G6PC, SLC37A4, etc.) all at once by next-generation sequencing (NGS).

Enzyme activity analysis (optional): when molecular genetic testing is inconclusive, PhK enzyme activity is measured directly by liver biopsy. Reduction of PhK activity in liver tissue to less than 5% of normal controls is the confirmatory criterion. Liver biopsy confirms excessive glycogen accumulation by PAS staining, and electron microscopy confirms a marked increase in glycogen particles of normal morphology.

Differential diagnosis: Hers disease (GSD VI, PYGL): clinical and enzyme activity results are similar, so it can be distinguished only by molecular genetic testing. GSD III (Forbes disease, AGL variants): may be accompanied by muscle involvement and cardiomyopathy; reduced debranching enzyme activity. GSD I (von Gierke disease, G6PC): distinguishable by more severe hypoglycemia, lactic acidemia, and uricemia. Other liver diseases (viral hepatitis, autoimmune liver disease, Wilson disease, fatty liver): excluded by specific diagnostic tests.


10. Treatment

As in GSD VI, treatment of GSD IX centers on dietary management. Currently, no fundamental treatments (enzyme replacement therapy, gene therapy) have received clinical approval. The goals of treatment are prevention of hypoglycemia and ketoacidosis, promotion of growth, and minimization of liver damage.

Dietary treatment: a high-protein (protein 20~25% of energy), low-carbohydrate (simple sugars restricted) diet centered on complex carbohydrates is maintained. Uncooked cornstarch (UCS) is digested slowly over a long period and maintains blood glucose, making it effective for preventing hypoglycemia; 1.5~2 g/kg is given before bedtime. Small, frequent meals (4~6 times a day) are eaten so that fasting periods do not exceed 6 hours. Sufficient food variety is ensured to prevent nutritional imbalance, and vitamin and mineral supplements are prescribed as needed.

Nocturnal continuous enteral nutrition (NCEN): in infants or severe patients (especially GSD IXc) whose blood glucose is insufficiently controlled with uncooked cornstarch, nocturnal continuous glucose infusion via nasogastric tube or gastrostomy is performed. NCEN effectively prevents nocturnal hypoglycemia, but the long-term need for it should be evaluated regularly and a transition plan made according to growth.

Management of complications: in patients with GSD IXc (PHKG2), abdominal ultrasound and AFP testing are performed every 6 months for early detection of progression of liver cirrhosis and development of hepatocellular carcinoma. When liver cirrhosis has progressed, liver transplantation may be considered as the only curative treatment. For hypertriglyceridemia, a low-fat, low-simple-sugar diet is reinforced, and omega-3 fatty acid supplementation is considered if needed. When bone density is reduced, calcium and vitamin D are supplemented and weight-bearing exercise is recommended.

Special considerations for GSD IXa: because hepatomegaly and hypoglycemia tend to improve spontaneously after puberty in boys with X-linked GSD IXa, the intensity of treatment can be reassessed in adulthood. However, it is recommended to maintain dietary management and regular follow-up until complete improvement.


11. Prognosis

The prognosis of GSD IX differs considerably by subtype. The prognosis of GSD IXa (PHKA2) is generally favorable. With appropriate dietary treatment, episodes of hypoglycemia and ketoacidosis are rare and growth normalizes. A tendency toward spontaneous improvement is observed after puberty, with marked reduction of hepatomegaly and normalization of liver function values. Serious long-term complications are rare, and intellectual and cardiopulmonary function remain normal. GSD IXb (PHKB) has a variable prognosis depending on whether muscle symptoms are present, and mild muscle weakness may persist. GSD IXc (PHKG2) has the poorest prognosis. Cases progressing to liver cirrhosis and liver failure when left untreated have been reported, and hepatocellular carcinoma can develop even in childhood and adolescence. Active dietary treatment and regular liver follow-up are essential for improving prognosis. Liver transplantation is sometimes required.

In general, with early diagnosis and appropriate dietary management, patients with GSD IX can maintain near-normal quality of life and life expectancy. However, patients with GSD IXc need intensive lifelong monitoring for hepatic complications.


12. Prevention

Genetic counseling is tailored to the mode of inheritance of the subtype. In GSD IXa (X-linked), when the mother is a PHKA2 carrier, 50% of sons are affected, so carrier identification and prenatal genetic testing are important. For GSD IXb/c (autosomal recessive), carrier testing of both parents and preimplantation genetic testing (PGT-M) or prenatal genetic testing are offered. As secondary prevention after diagnosis, dietary treatment is started immediately to prevent chronic occurrence of hypoglycemia and ketoacidosis. An emergency dietary protocol is established, and families are educated so they can respond immediately to fever, vomiting, or fasting. In patients with GSD IXc, regular imaging surveillance for early detection of liver cirrhosis and hepatocellular carcinoma (ultrasound and AFP every 6 months) is an essential tertiary prevention measure. Hepatotoxic drugs and alcohol intake are strictly avoided, and special care is needed with potentially hepatotoxic medications when liver function is abnormal.


13. References

  1. Beauchamp NJ, Dalton A, Ramaswami U, et al. Glycogen storage disease type IX: high variability in clinical phenotype. Mol Genet Metab. 2007;92(1-2):88-99. DOI: 10.1016/j.ymgme.2007.06.007. PMID: 17643334.

  2. Davit-Spraul A, Piraud M, Dobbelaere D, et al. Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies. Mol Genet Metab. 2011;104(1-2):137-143. DOI: 10.1016/j.ymgme.2011.06.010. PMID: 21741270.

  3. Roscher A, Patel J, Hewson S, et al. The natural history of glycogen storage disease types VI and IX: long-term outcome from the largest metabolic center in Canada. Mol Genet Metab. 2014;113(3):171-176. DOI: 10.1016/j.ymgme.2014.09.005. PMID: 25283467.

  4. Tsilianidis LA, Fiske LM, Siegel S, et al. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab. 2013;109(3):179-182. DOI: 10.1016/j.ymgme.2013.03.016. PMID: 23618865.

  5. Burwinkel B, Shin YS, Bakker HD, et al. Mutation hotspots in the PHKA2 gene in X-linked liver glycogenosis: control of cyclic AMP-stimulated and basal phosphorylase kinase activity. Hum Mol Genet. 1996;5(2):189-196. DOI: 10.1093/hmg/5.2.189. PMID: 8824878.

  6. Maichele AJ, Burwinkel B, Maire I, et al. Mutations in testis/liver phosphorylase kinase gene associated with liver glycogenosis in men and boys. Nat Genet. 1996;14(3):337-340. DOI: 10.1038/ng1196-337. PMID: 8896565.

  7. Willems PJ, Gerver WJ, Berger R, et al. The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. Eur J Pediatr. 1990;149(4):268-271. DOI: 10.1007/bf01958290. PMID: 2302940.

  8. Bali DS, Goldstein JL, Fredrickson K, et al. Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene. Mol Genet Metab. 2014;111(3):309-313. DOI: 10.1016/j.ymgme.2013.12.008. PMID: 24412167.

  9. Bhavsar S, Bhavsar A, Diaz GA, et al. Understanding Glycogen Storage Disease Type IX: A Systematic Review with Clinical Focus—Why It Is Not Benign and Requires Vigilance. Genes (Basel). 2025;16(5):584. DOI: 10.3390/genes16050584. PMID: 40427286.

  10. Hendriksz CJ, Bhattacharya K, Bhavsar S, et al. Glycogen storage disorder IXb exploring clinical patterns in PHKB-associated GSD. Cureus. 2024;16(7):e65373. DOI: 10.7759/cureus.65373. PMID: 39184568.